Ruijian Medicine's NouvNeu001 Becomes First iPSC-Derived Therapy Globally to Receive FDA Fast Track and RMAT Dual Designations for Parkinson’s Disease
iRegene Therapeutics
Cell Therapy Product Developer
On December 24, iRegene announced that its independently developed NouvNeu001 injection had been granted by the FDA on December 22.Advanced Regenerative Medicine Therapies（RMAT）RecognitionIn August this year, the FDA granted the drug Fast Track designation for the treatment of Parkinson's disease.（FTD）。iRegene Press Release Points Out, NouvNeu001 Is So FarThe World's First IPSC Product to Receive Dual FDA FTD and RMAT Designations。
RMAT stands for Regenerative Medicine Advanced Therapy, an accelerated approval pathway established by the 21st Century Cures Act of 2016. It is specifically designed for regenerative medicine therapies, focusing on significant clinical value to facilitate their rapid market entry and address unmet medical needs.
Screenshot source: Official WeChat account of the company
As the world's second-largest neurodegenerative disease, the current therapeutic positioning for Parkinson's disease is either symptomatic or "complication management," rather than a "disease-modifying" treatment. The development of NouvNeu001 directly addresses this fundamental treatment gap.Aiming to fundamentally repair the loss of dopaminergic neurons through cell replacement therapy and reverse the progression of Parkinson's disease., bringing clinical benefits to patients that may alter the course of the disease.
According to the introduction, iRegene's proprietary "AI + chemical induction" technology can achieve directed differentiation of high-purity specific dopaminergic neuron subtypes. During the induction process, it simultaneously completes various functional modifications, including cellular biochemistry, to meet genuine clinical needs. After transplantation, the cells fill the gap of missing functional cells at the lesion site, ultimately repairing the circuit loss caused by Parkinson’s disease in patients and restoring their ability to secrete dopamine autonomously—a potential for reversing disease progression that traditional symptomatic treatments cannot achieve.
Compared with global peers, iRegene adopts the world's first single-needle stereotactic drug delivery method, achieving maximum safety in the drug delivery process and enabling long-term survival and integration of transplanted cells. Its efficacy data also demonstrate internationally leading potential, with subjects showing motor function scores 12 months after a single dose.（MDS-UPDRS III）An average improvement of 30.6 points in the OFF state(Improvement Amplitude 52.82%)，ON status improved by an average of 13.6 points(Improvement Amplitude 54.67%), significantly superior to existing therapies.
iRegene's NouvNeu001 has demonstrated data integrity, clinical trial rigor, and superior safety and efficacy in Phase I clinical trials for Parkinson's disease. The dual qualifications of FTD and RMAT reflect the FDA's high recognition of these data. The FDA will further engage in close communication with iRegene to provide customized guidance for subsequent clinical development, including in-depth discussions on trial design, selection of clinical endpoints, and accelerated approval pathways, thereby shortening the time from clinical trials to market.
